Novo Nordisk
NVO
550 hedge funds and large institutions have $7.99B invested in Novo Nordisk in 2018 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 162 increasing their positions, 196 reducing their positions, and 77 closing their positions.
142% more call options, than puts
Call options by funds: $78.1M | Put options by funds: $32.3M
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
1% more capital invested
Capital invested by funds: $7.89B → $7.99B (+$93.6M)
0.62% more ownership
Funds ownership: 17.53% → 18.15% (+0.62%)
4% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 77
1% less funds holding
Funds holding: 558 → 550 (-8)
17% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 196
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$188M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$96.4M |
| 3 |
Renaissance Technologies
New York
|
+$47.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.6M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$44.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$29.8M |
| 3 |
BlackRock
New York
|
-$24.9M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$21.8M |
| 5 |
LIM
Lagoda Investment Management
New York
|
-$14.8M |
NVO Hedge Fund Activity: Q4 2018 in Review
550 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2018, worth a combined $7.99B — up 1.2% from $7.89B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of NVO and 74 opened new positions — a net loss of 3 holders — while 196 trimmed existing stakes and 162 added.
The largest buyer was Arrowstreet Capital, adding an estimated $188M. The largest seller was Loomis, Sayles & Company, cutting an estimated $44.6M.
- 550 institutional investors held Novo Nordisk (NVO) as of Q4 2018, down from 558 in Q3 2018.
- Funds reported $7.99B of Novo Nordisk stock for Q4 2018, up 1.2% quarter-over-quarter.
- 74 funds opened new Novo Nordisk positions in Q4 2018 and 77 closed out, a net change of -3 holders.
- The largest Novo Nordisk buyer in Q4 2018 was Arrowstreet Capital, an estimated $188M added.
- The largest Novo Nordisk seller in Q4 2018 was Loomis, Sayles & Company, an estimated $44.6M sold.
Based on aggregated 13F filings for Q4 2018.